Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IDN-6556 Dose Response in Chronic Hepatitis C
NCT00088140Phase 2Completed
- Sponsor
- Conatus Pharmaceuticals Inc.
- Start
- Jul 2004
- Primary completion
- Oct 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of emricasan in hepatitis C (HCV) (4 arms), sponsored by Conatus Pharmaceuticals Inc. Primary endpoints: Median absolute change in aspartate transaminase (AST) values at Week 10 and Median absolute change in alanine aminotransferase (ALT) values at Week 10. Started Jul 2004; status: completed.
02
Drugs
emricasan
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT00088140.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00088140.